152 Chapter 6 25. Meyer PT, Hellwig S, Amtage F, Rottenburger C, Sahm U, Reuland P, et al. Dualbiomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011;52(3):393-400. 26. Hays CC, Zlatar ZZ, Wierenga CE. The Utility of Cerebral Blood Flow as a Biomarker of Preclinical Alzheimer’s Disease. Cellular and molecular neurobiology. 2016;36(2):167-79. 27. Slot RER, Verfaillie SCJ, Overbeek JM, Timmers T, Wesselman LMP, Teunissen CE, et al. Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. Alzheimers Res Ther. 2018;10(1):76. 28. van der Flier WM, Scheltens P. Amsterdam Dementia Cohort: Performing Research to Optimize Care. Journal of Alzheimer’s disease : JAD. 2018;62(3):1091-111. 29. van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. Journal of Alzheimer’s disease : JAD. 2014;41(1):313-27. 30. Hammers A, Allom R, Koepp MJ, Free SL, Myers R, Lemieux L, et al. Threedimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Human brain mapping. 2003;19(4):224-47. 31. Lammertsma AA. Forward to the Past: The Case for Quantitative PET Imaging. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2017;58(7):1019-24. 32. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligandreceptor binding in PET using a simplified reference region model. NeuroImage. 1997;6(4):279-87. 33. Verfaillie SCJ, Golla SSV, Timmers T, Tuncel H, van der Weijden CWJ, Schober P, et al. Repeatability of parametric methods for [18F]florbetapir imaging in Alzheimer’s disease and healthy controls: A test–retest study. Journal of Cerebral Blood Flow & Metabolism. 2020:0271678X20915403. 34. Joshi AD, Pontecorvo MJ, Lu M, Skovronsky DM, Mintun MA, Devous MD, Sr. A Semiautomated Method for Quantification of F 18 Florbetapir PET Images. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2015;56(11):1736-41. 35. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR American journal of roentgenology. 1987;149(2):351-6. 36. Timmers T, Ossenkoppele R, Verfaillie SCJ, van der Weijden CWJ, Slot RER, Wesselman LMP, et al. Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project. Neurobiology of aging. 2019;79:50-8. 37. Park KW, Yoon HJ, Kang DY, Kim BC, Kim S, Kim JW. Regional cerebral blood flow differences in patients with mild cognitive impairment between those who did and did not develop Alzheimer’s disease. Psychiatry research. 2012;203(2-3):201-6. 38. Wolters FJ, Zonneveld HI, Hofman A, van der Lugt A, Koudstaal PJ, Vernooij MW, et al. Cerebral Perfusion and the Risk of Dementia: A Population-Based Study. Circulation. 2017;136(8):719-28.
RkJQdWJsaXNoZXIy MjY0ODMw